An Investigator Initiated Study to Evaluate the Safety and Efficacy of Aminolevulinic Acid Hydrochloride Topical Gel, 10% (Ameluz ®) With RhodoLED-XL® Red Light in the Treatment of Facial Cutaneous Squamous Cell Carcinoma in Situ (SCCis)"

In the study, participants will be asked to complete the following:

• Provide basic personal information (including date of birth, gender, race and ethnicity)
• Provide their medical/ surgical history and perform a medical exam (including but not limited to symptom-directed physical exam, skin type, vital signs, height, weight and urine pregnancy test collection)
• Follow study rules such as avoiding certain medications and treatments
• Provide information on any medications, treatments or reactions that started after the study began
• Allow two treatments on the skin cancer area of the face using a light-sensitive cream used in combination with a light source
• Allow clinical documentation of the treatment, such as how well the treatment was tolerated, any skin reaction or side effects
• Allow surgery to remove the skin cancer area from the face for Laboratory testing

To qualify for this trial, participants must:

• be an adult (18 years of age or older)
• give voluntary written consent
• have a recently diagnosed (less than six months from first visit) skin cancer area on the face that meets surgery size requirements
• be willing to follow study instructions and complete study requirements, including not using non-approved lotions and creams on the treatments areas
• allow photographs of the area of skin cancer being treated on the face
• (if female) not be pregnant before and during the study and agree to use acceptable forms of birth control
• confirm they are not sensitive to any of the study treatment ingredients

All surgery samples collected from the participants towards the end of the study will be sent to a laboratory for testing. All photographs of the treatment area collected during the study will be used as study data.